INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS
申请人:TRUSTEES OF BOSTON UNIVERSITY
公开号:US20170107227A1
公开(公告)日:2017-04-20
The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III′) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
US9802948B2
申请人:——
公开号:US9802948B2
公开(公告)日:2017-10-31
[EN] LATE SV40 FACTOR (LSF) INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR SV40 TARDIF (LSF)
申请人:UNIV BOSTON
公开号:WO2020028757A1
公开(公告)日:2020-02-06
The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. heptacellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.